№ lp_2_3_53745
File format: docx Character count: 41154 File size: 369 KB
Year: 2023
Region / city: Australia
Topic: Pneumococcal vaccination
Document type: Submission
Agency / organization: Australian Technical Advisory Group on Immunisation (ATAGI)
Author: Merck Sharp & Dohme (Australia) Pty Ltd
Target audience: Healthcare professionals involved in immunization
Period of validity: Not specified
Approval date: Expected by 30 April 2023
Date of changes: 9 February 2023
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE, 15 VALENT ADSORBED, 0.5 mL pre-filled syringe, Vaxneuvance® Merck Sharp & Dohme (Australia) Pty Ltd.
Year: 2021
Region / City: Australia
Topic: Pneumococcal vaccine submission
Document type: Submission for listing on the National Immunisation Program
Author: Merck Sharp & Dohme (Australia) Pty Ltd
Target audience: Health professionals, regulatory bodies, policy makers
Period of validity: Ongoing
Approval date: 16 July 2021 (FDA approval), 14 October 2021 (EMA recommendation)
Date of changes: Not specified
Context: A clinical submission for the inclusion of a 15-valent pneumococcal conjugate vaccine (PCV15) on the National Immunisation Program for adults at risk of pneumococcal disease.
PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE, 15 VALENT ADSORBED, 0.5 mL pre-filled syringe, Vaxneuvance® Merck Sharp & Dohme (Australia) Pty Ltd.
Year: 2021
Region / City: Australia
Topic: Pneumococcal vaccine submission
Document type: Submission for listing on the National Immunisation Program
Author: Merck Sharp & Dohme (Australia) Pty Ltd
Target audience: Health professionals, regulatory bodies, policy makers
Period of validity: Ongoing
Approval date: 16 July 2021 (FDA approval), 14 October 2021 (EMA recommendation)
Date of changes: Not specified
Context: A clinical submission for the inclusion of a 15-valent pneumococcal conjugate vaccine (PCV15) on the National Immunisation Program for adults at risk of pneumococcal disease.
Pneumococcal polysaccharide conjugate vaccine (adsorbed) Patient Group Direction (PGD)
Year: 2025
Region / city: England
Topic: Immunization
Document type: Patient Group Direction (PGD)
Organization / institution: UK Health Security Agency (UKHSA)
Author: Suki Hunjunt, Professor Shamez Ladhani, David Green
Target audience: Healthcare professionals involved in immunization
Period of validity: From 5 January 2026 to 5 January 2029
Approval date: 5 January 2026
Amendment date: 2 June 2025, 16 December 2025
Description: A document detailing the administration guidelines for the pneumococcal polysaccharide conjugate vaccine (PCV13, PCV15) for children under 2 years old in the UK.
Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) (PCV20) Patient Group Direction (PGD)
Year: 2025
Region / city: England
Topic: Immunization
Document type: Patient Group Direction (PGD)
Authoring body: UK Health Security Agency (UKHSA)
Target audience: Healthcare professionals involved in immunization programs
Period of validity: 17 December 2025 - 17 December 2028
Approval date: 9 December 2025
Review date: 17 July 2028
Expiry date: 17 December 2028
PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE, 15 VALENT ADSORBED, 0.5 mL pre-filled syringe, Vaxneuvance® Merck Sharp & Dohme (Australia) Pty Ltd.
Year: 2021
Region / City: Australia
Topic: Pneumococcal vaccine submission
Document type: Submission for listing on the National Immunisation Program
Author: Merck Sharp & Dohme (Australia) Pty Ltd
Target audience: Health professionals, regulatory bodies, policy makers
Period of validity: Ongoing
Approval date: 16 July 2021 (FDA approval), 14 October 2021 (EMA recommendation)
Date of changes: Not specified
Context: A clinical submission for the inclusion of a 15-valent pneumococcal conjugate vaccine (PCV15) on the National Immunisation Program for adults at risk of pneumococcal disease.
PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE, 13-VALENT ADSORBED
Year: 2016
Region / City: Australia
Theme: Pneumococcal disease prevention
Document Type: Submission
Organization / Institution: Pfizer Australia Pty Ltd
Author: Pfizer Australia Pty Ltd
Target Audience: Healthcare professionals, policymakers, public health authorities
Period of Validity: Not specified
Approval Date: Not specified
Date of Changes: Not specified
Advanced optical spectroscopies for studying the interactions and reactivity of atmospheric pollutants adsorbed in photoactive porous materials (from October 2024)
Year: 2024
Location: Lille, France
Topic: Interaction and reactivity of atmospheric pollutants in porous materials
Document type: PhD proposal
Institution: Laboratory of Spectroscopy for Interactions, Reactivity and Environment (LASIRE), University of Lille
Collaborating institution: Hybrid Materials (MATHYB) team, Unité de Catalyse et Chimie du Solide (UCCS)
Supervisor: Pr. Alain Moissette
Target audience: PhD candidates in Chemistry or Physical Chemistry
Funding: Planned co-funding from Region Hauts de France
Required qualifications: Master in Chemistry or Physical Chemistry, specialization in micro- and nano-porous materials or photochemistry and spectroscopy of solids
Keywords: Metal Organic Framework (MOF), vibrational optical spectroscopy, time-resolved spectroscopy
Application procedure: Submission of CV, motivation letter, and academic transcripts
Topics: VALENT Vaxneuvance adsorbed